Fresh off a presentation of positive data showing that the KRASG12C inhibitor adagrasib benefited colorectal and lung cancer patients, Mirati Therapeutics forged an agreement to combine the drug with Sanofi’s company’s SHP2 inhibitor SAR442720 in lung cancer.
With $19 million in seed funding led by the Retinal Degeneration Fund, Opus Genetics launched with a mission to develop gene therapies for rare forms of blindness driven by genetic mutations.
Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
The Covid-19 variant C.1.2., which was first detected in South Africa in May 2021, is causing public health experts worldwide to keep an eye out for its presence as it seems to be more infectious and even more resistant to vaccines than other variants.
U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.
Research published in Trends in Genetics by Dr. Leslie Lyons, Gilbreath-McLorn endowed professor of comparative medicine at the University of Missouri College of Veterinary Medicine, could be instrumental to the development of personalized therapeutics for both two-legged and four-legged patients.
The U.S. Food and Drug Administration placed a clinical hold on Boston-based Aprea Therapeutics’ lymphoid malignancy trial after the regulatory agency expressed concerns regarding the safety and efficacy data from a previous myelodysplastic syndromes (MDS) study.
The continued spread of the SARS-CoV-2 virus has spawned a Greek alphabet of variants – a naming system used by the World Health Organization to track concerning new mutations of the virus that causes Covid-19. Some have equipped the virus with better ways of infecting humans or evading vaccine protection.
California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.